GlobeNewswire Inc.··Xortx Therapeutics Inc.XORTX Therapeutics Completes 1-for-5 Share Consolidation Effective April 6
XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.
XRTXclinical trialskidney disease